Online inquiry

IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2188MR)

This product GTTS-WQ2188MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000585.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3600
UniProt ID P40933
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2188MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12631MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ10955MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ8238MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ5176MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ9522MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ7468MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ5003MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ10543MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3015014
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW